GlassScriptPhysician profile
Brian L Holmes
NPI 1346350931
$2,019.67
in general payments reported to CMS, 2019-2025
22 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $215 · 2021: $425 · 2022: $282 · 2023: $217 · 2024: $188 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $305.96 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $267.44 | 2019-2025 | |
| Amgen INC. | $219.44 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $170.94 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $128.84 | 2021-2023 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $114.32 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $108.58 | 2024-2025 | Rexulti |
| Eisai INC. | $94.30 | 2020-2021 | |
| Corcept Therapeutics | $85.96 | 2025 | Korlym |
| Abbvie INC. | $84.89 | 2022-2024 | |
| Grifols USA, LLC | $66.19 | 2024-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $54.29 | 2020-2021 | |
| Glaxosmithkline, LLC. | $50.57 | 2022-2025 | Bexsero, Pediarix, Penmenvy |
| Astrazeneca Pharmaceuticals LP | $47.41 | 2020-2022 | |
| Electromed, INC. | $46.22 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.51 | 2021-2022 | |
| Amarin Pharma, INC. | $29.50 | 2020-2021 | |
| Vapotherm INC | $29.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.23 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $21.69 | 2021 | |
| Acadia Pharmaceuticals INC | $18.32 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.